Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function

Molecular Cell

Volumn 58, Issue 6, 2015, Pages 925-934

  Feng, Felix Y ^a,b   de Bono, Johann S ^c   Rubin, Mark A ^d,e   Knudsen, Karen E ^f,g  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; GLYCOSYLTRANSFERASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1 INHIBITOR; UNCLASSIFIED DRUG; CHROMATIN; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARP1 PROTEIN, HUMAN;

CANCER THERAPY; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; DISEASE MANAGEMENT; DNA BINDING; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; GENE EXPRESSION; GENOMIC INSTABILITY; HISTONE MODIFICATION; HUMAN; NONHUMAN; PROGRESSION FREE SURVIVAL; REVIEW; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

CHROMATIN; DNA REPAIR; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; TRANSCRIPTION, GENETIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84937606000     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.04.016     Document Type: Review

References (80)

1. Ahel I., Ahel D., Matsusaka T., Clark A.J., Pines J., Boulton S.J., West S.C. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 2008, 451:81-85.
2. Alvarez-Gonzalez R., Althaus F.R. Poly(ADP-ribose) catabolism in mammalian cells exposed to DNA-damaging agents. Mutat. Res. 1989, 218:67-74.
3. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
4. Bai P., Virág L. Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes. FEBS Lett. 2012, 586:3771-3777.
5. Bai P., Nagy L., Fodor T., Liaudet L., Pacher P. Poly(ADP-ribose) polymerases as modulators of mitochondrial activity. Trends Endocrinol. Metab. 2015, 26:75-83.
6. Bang Y.J., Al E., Al E. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study. J. Clin. Oncol. 2013, 31:a4013.
7. Barkauskaite E., Jankevicius G., Ladurner A.G., Ahel I., Timinszky G. The recognition and removal of cellular poly(ADP-ribose) signals. FEBS J. 2013, 280:3491-3507.
8. Beck C., Robert I., Reina-San-Martin B., Schreiber V., Dantzer F. Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3. Exp. Cell Res. 2014, 329:18-25.
9. Brenner J.C., Ateeq B., Li Y., Yocum A.K., Cao Q., Asangani I.A., Patel S., Wang X., Liang H., Yu J., et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011, 19:664-678.
10. Bryant H.E., Petermann E., Schultz N., Jemth A.S., Loseva O., Issaeva N., Johansson F., Fernandez S., McGlynn P., Helleday T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009, 28:2601-2615.
11. Chang W.J., Alvarez-Gonzalez R. The sequence-specific DNA binding of NF-kappa B is reversibly regulated by the automodification reaction of poly (ADP-ribose) polymerase 1. J. Biol. Chem. 2001, 276:47664-47670.
12. Curtin N.J., Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Aspects Med. 2013, 34:1217-1256.
13. Durrant L.G., Boyle J.M. Potentiation of cell killing by inhibitors of poly(ADP-ribose) polymerase in four rodent cell lines exposed to N-methyl-N-nitrosourea or UV light. Chem. Biol. Interact. 1982, 38:325-338.
14. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
15. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361:123-134.
16. Frizzell K.M., Gamble M.J., Berrocal J.G., Zhang T., Krishnakumar R., Cen Y., Sauve A.A., Kraus W.L. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. J. Biol. Chem. 2009, 284:33926-33938.
17. Gagné J.P., Hendzel M.J., Droit A., Poirier G.G. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr. Opin. Cell Biol. 2006, 18:145-151.
18. Gibson B.A., Kraus W.L. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 2012, 13:411-424.
19. Golia B., Singh H.R., Timinszky G. Poly-ADP-ribosylation signaling during DNA damage repair. Front Biosci (Landmark Ed) 2015, 20:440-457.
20. Goodwin J.F., Knudsen K.E. Beyond DNA repair: DNA-PK function in cancer. Cancer Discov 2014, 4:1126-1139.
21. Goodwin J.F., Schiewer M.J., Dean J.L., Schrecengost R.S., de Leeuw R., Han S., Ma T., Den R.B., Dicker A.P., Feng F.Y., Knudsen K.E. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 2013, 3:1254-1271.
22. Gottschalk A.J., Timinszky G., Kong S.E., Jin J., Cai Y., Swanson S.K., Washburn M.P., Florens L., Ladurner A.G., Conaway J.W., Conaway R.C. Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc. Natl. Acad. Sci. USA 2009, 106:13770-13774.
23. Ha H.C., Hester L.D., Snyder S.H. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc. Natl. Acad. Sci. USA 2002, 99:3270-3275.
24. Hassa P.O., Hottiger M.O. A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol. Chem. 1999, 380:953-959.
25. Hassa P.O., Hottiger M.O. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell. Mol. Life Sci. 2002, 59:1534-1553.
26. Helleday T., Bryant H.E., Schultz N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005, 4:1176-1178.
27. Horton J.K., Wilson S.H. Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity. Front Oncol 2013, 3:257.
28. Iliakis G. Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. Radiother. Oncol. 2009, 92:310-315.
29. Jankevicius G., Hassler M., Golia B., Rybin V., Zacharias M., Timinszky G., Ladurner A.G. A family of macrodomain proteins reverses cellular mono-ADP-ribosylation. Nat. Struct. Mol. Biol. 2013, 20:508-514.
30. Ji Y., Tulin A.V. The roles of PARP1 in gene control and cell differentiation. Curr. Opin. Genet. Dev. 2010, 20:512-518.
31. Ju B.G., Solum D., Song E.J., Lee K.J., Rose D.W., Glass C.K., Rosenfeld M.G. Activating the PARP-1 sensor component of the groucho/ TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent neurogenic gene activation pathway. Cell 2004, 119:815-829.
32. Jwa M., Chang P. PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1α-mediated unfolded protein response. Nat. Cell Biol. 2012, 14:1223-1230.
33. Kameoka M., Ota K., Tetsuka T., Tanaka Y., Itaya A., Okamoto T., Yoshihara K. Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase. Biochem. J. 2000, 346:641-649.
34. Kraus W.L., Hottiger M.O. PARP-1 and gene regulation: progress and puzzles. Mol. Aspects Med. 2013, 34:1109-1123.
35. Krishnakumar R., Kraus W.L. PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol. Cell 2010, 39:736-749.
36. Krishnakumar R., Gamble M.J., Frizzell K.M., Berrocal J.G., Kininis M., Kraus W.L. Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 2008, 319:819-821.
37. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C., Meier W., Shapira-Frommer R., Safra T., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 2012, 366:1382-1392.
38. Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., Scott C.L., Meier W., Shapira-Frommer R., Safra T., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014, 15:852-861.
39. Li M., Yu X. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene 2014, Published online September 15, 2014. 10.1038/onc.2014.295.
40. Liu L., Taverna P., Whitacre C.M., Chatterjee S., Gerson S.L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res. 1999, 5:2908-2917.
41. Liu Y., Kadyrov F.A., Modrich P. PARP-1 enhances the mismatch-dependence of 5'-directed excision in human mismatch repair in vitro. DNA Repair (Amst.) 2011, 10:1145-1153.
42. Luo X., Kraus W.L. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 2012, 26:417-432.
43. Lupo B., Trusolino L. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim. Biophys. Acta 2014, 1846:201-215.
44. Martin-Oliva D., Aguilar-Quesada R., O'valle F., Muñoz-Gámez J.A., Martínez-Romero R., García Del Moral R., Ruiz de Almodóvar J.M., Villuendas R., Piris M.A., Oliver F.J. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 2006, 66:5744-5756.
45. Masutani M., Nozaki T., Nishiyama E., Shimokawa T., Tachi Y., Suzuki H., Nakagama H., Wakabayashi K., Sugimura T. Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. Mol. Cell. Biochem. 1999, 193:149-152.
46. Mateo J., Hall E., Sandhu S.K., Omlin A.G., Miranda S., Carreira S., Goodall J., Gillman A., Mossop H., Ralph C., et al. Antitumour activity of the PARP inhibitor olaparib in unselected sporadic castration-resistant prostate cancer (CRPC) in the TOPARP trial. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2014, 25:1-41.
47. Matsuura S., Egi Y., Yuki S., Horikawa T., Satoh H., Akira T. MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Res. 2011, 1410:122-131.
48. McCabe N., Turner N.C., Lord C.J., Kluzek K., Bialkowska A., Swift S., Giavara S., O'Connor M.J., Tutt A.N., Zdzienicka M.Z., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006, 66:8109-8115.
49. Morrow D.A., Brickman C.M., Murphy S.A., Baran K., Krakover R., Dauerman H., Kumar S., Slomowitz N., Grip L., McCabe C.H., Salzman A.L. A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J. Thromb. Thrombolysis 2009, 27:359-364.
50. Murai J., Huang S.Y., Das B.B., Renaud A., Zhang Y., Doroshow J.H., Ji J., Takeda S., Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012, 72:5588-5599.
51. Nduka N., Skidmore C.J., Shall S. The enhancement of cytotoxicity of N-methyl-N-nitrosourea and of gamma-radiation by inhibitors of poly(ADP-ribose) polymerase. Eur. J. Biochem. 1980, 105:525-530.
52. O'Shaughnessy J., Schwartzberg L., Danso M.A., Miller K.D., Rugo H.S., Neubauer M., Robert N., Hellerstedt B., Saleh M., Richards P., et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 2014, 32:3840-3847.
53. Oliver F.J., Ménissier-de Murcia J., Nacci C., Decker P., Andriantsitohaina R., Muller S., de la Rubia G., Stoclet J.C., de Murcia G. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999, 18:4446-4454.
54. Oza A.M., Cibula D., Benzaquen A.O., Poole C., Mathijssen R.H., Sonke G.S., Colombo N., Špaček J., Vuylsteke P., Hirte H., et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015, 16:87-97.
55. Patel A.G., De Lorenzo S.B., Flatten K.S., Poirier G.G., Kaufmann S.H. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 2012, 18:1655-1662.
56. Petesch S.J., Lis J.T. Activator-induced spread of poly(ADP-ribose) polymerase promotes nucleosome loss at Hsp70. Mol. Cell 2012, 45:64-74.
57. Polkinghorn W.R., Parker J.S., Lee M.X., Kass E.M., Spratt D.E., Iaquinta P.J., Arora V.K., Yen W.F., Cai L., Zheng D., et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013, 3:1245-1253.
58. Prensner J.R., Chen W., Iyer M.K., Cao Q., Ma T., Han S., Sahu A., Malik R., Wilder-Romans K., Navone N., et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014, 74:1651-1660.
59. Robert I., Dantzer F., Reina-San-Martin B. Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. J. Exp. Med. 2009, 206:1047-1056.
60. Robinson D., Van Allen E.M., Wu Y.M., Schultz N., Lonigro R.J., Mosquera J.M., Montgomery B., Taplin M.E., Pritchard C.C., Attard G., et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015, 161:1215-1228.
61. Robu M., Shah R.G., Petitclerc N., Brind'Amour J., Kandan-Kulangara F., Shah G.M. Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair. Proc. Natl. Acad. Sci. USA 2013, 110:1658-1663.
62. Rulten S.L., Fisher A.E., Robert I., Zuma M.C., Rouleau M., Ju L., Poirier G., Reina-San-Martin B., Caldecott K.W. PARP-3 and APLF function together to accelerate nonhomologous end-joining. Mol. Cell 2011, 41:33-45.
63. Sala A., La Rocca G., Burgio G., Kotova E., Di Gesù D., Collesano M., Ingrassia A.M., Tulin A.V., Corona D.F. The nucleosome-remodeling ATPase ISWI is regulated by poly-ADP-ribosylation. PLoS Biol. 2008, 6:e252.
64. Sandhu S.K., Yap T.A., de Bono J.S. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur. J. Cancer 2010, 46:9-20.
65. Schiewer M.J., Knudsen K.E. Transcriptional roles of PARP1 in cancer. Mol. Cancer Res. 2014, 12:1069-1080.
66. Schiewer M.J., Goodwin J.F., Han S., Brenner J.C., Augello M.A., Dean J.L., Liu F., Planck J.L., Ravindranathan P., Chinnaiyan A.M., et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012, 2:1134-1149.
67. Shall S., de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?. Mutat. Res. 2000, 460:1-15.
68. Slade D., Dunstan M.S., Barkauskaite E., Weston R., Lafite P., Dixon N., Ahel M., Leys D., Ahel I. The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase. Nature 2011, 477:616-620.
69. Sonnenblick A., de Azambuja E., Azim H.A., Piccart M. An update on PARP inhibitors-moving to the adjuvant setting. Nat. Rev. Clin. Oncol. 2015, 12:27-41.
70. Steffen J.D., Brody J.R., Armen R.S., Pascal J.M. Structural Implications for Selective Targeting of PARPs. Front Oncol 2013, 3:301.
71. Szabó C., Zingarelli B., O'Connor M., Salzman A.L. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl. Acad. Sci. USA 1996, 93:1753-1758.
72. Tentori L., Leonetti C., Scarsella M., d'Amati G., Portarena I., Zupi G., Bonmassar E., Graziani G. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 2002, 99:2241-2244.
73. Thomas C.J., Kotova E., Andrake M., Adolf-Bryfogle J., Glaser R., Regnard C., Tulin A.V. Kinase-mediated changes in nucleosome conformation trigger chromatin decondensation via poly(ADP-ribosyl)ation. Mol. Cell 2014, 53:831-842.
74. Timinszky G., Till S., Hassa P.O., Hothorn M., Kustatscher G., Nijmeijer B., Colombelli J., Altmeyer M., Stelzer E.H., Scheffzek K., et al. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat. Struct. Mol. Biol. 2009, 16:923-929.
75. Tutt A., Robson M., Garber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., Friedlander M., Arun B., Loman N., Schmutzler R.K., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
76. Virág L., Jagtap P., Szabó E., Mabley J.G., Liaudet L., Marton A., Hoyt D.G., Murthy K.G., Salzman A.L., Southan G.J., Szabó C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. 2001, 7:108-113. Garcia Soriano F.
77. Wang Z.Q., Auer B., Stingl L., Berghammer H., Haidacher D., Schweiger M., Wagner E.F. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 1995, 9:509-520.
78. Wang M., Wu W., Wu W., Rosidi B., Zhang L., Wang H., Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006, 34:6170-6182.
79. Ying S., Hamdy F.C., Helleday T. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res. 2012, 72:2814-2821.
80. Zhang Y., Wang J., Ding M., Yu Y. Site-specific characterization of the Asp- and Glu-ADP-ribosylated proteome. Nat. Methods 2013, 10:981-984.